Primary chemotherapy or hormonotherapy for patients with breast cancer

Cancer Treatment Reviews

Volumn 25, Issue 4, 1999, Pages 187-197

  Brain, Etienne G C ^a   Misset, Jean Louis ^b   Rouëssé, Jacques ^a  

^a CENTRE RENÉ HUGUENIN   (France)

^b HÔPITAL PAUL BROUSSE   (France)

Author keywords

Breast cancer; Chemotherapy; Hormonotherapy; Primary medical treatment

Indexed keywords

ANTHRACYCLINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; TAMOXIFEN; THIOTEPA; VINCRISTINE; VINDESINE;

ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; ANGIOGENESIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER STAGING; CANCER SURVIVAL; CONSERVATIVE TREATMENT; FEMALE; HUMAN; LYMPH NODE; MASTECTOMY; PATHOLOGY; PROGNOSIS; RECURRENCE RISK; REVIEW; SIDE EFFECT; TUMOR VOLUME;

EID: 0032868755     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1053/ctrv.1998.0118     Document Type: Review

References (52)

1. Fisher B., Gunduz N., Saffer E. A. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res. 43:1983;1488-1492.
2. Gunduz N., Fisher B., Saffer E. A. Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res. 39:1979;3861-3865.
3. O'Reilly M. S., Holmgren L., Chen C., Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med. 2:1996;689-692.
4. Swain S. M. Selection of therapy for stage III breast cancer. Surg Clin North America. 70:1990;1061-1080.
5. Jaiyesimi I. A., Buzdar A. U., Hortobagyi G. N. Inflammatory breast cancer: a review. J Clin Oncol. 10:1992;1014-1024.
6. Danforth D. Jr, Jacobson J., O'Shaughnessy J. Effect of preoperative chemotherapy on axillary lymph node metastases in stage II breast cancer: a propspective randomized trial. Proc Am Soc Clin Oncol. 14:1995.
7. Fisher B., Bryant J., Wolmark N. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 16:1998;2672-2685.
8. Gazet J. C., Ford H. T., Bland J. M., Markopoulos Ch, Coombes R. C., Dixon R. C. Prospective randomised trial of tamoxifen versus surgery in elderly patients with breast cancer. Lancet. 1:1988;679-681.
9. Makris A., Powles T. J., Ashley S. E. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol. 9:1998;1179-1184.
10. Mauriac L., Durand M., Avril A., Dilhuydy J. M. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Ann Oncol. 2:1991;347-354.
11. Mauriac L., Mac Grogan G., Avril A. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with 124-month median follow-up. Ann Oncol. 1999.
12. Powles T. J., Hickish T. F., Makris A. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol. 13:1995;547-552.
13. Roberston J. F. R., Ellis I. O., Elston C. W., Blamey R. W. Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients: 5-year follow-up. Eur J Cancer. 28A:1992;908-910.
14. Roberston J. F. R., Todd J. H., Ellis I. O., Elston C. W., Blamey R. W. Comparison of mastectomy with tamoxifen for treating elderly patients with operable breast cancer. Br Med J. 297:1988;511-514.
15. Scholl S. M., Asselain B., Beuzeboc P. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery. An update. Proc Am Soc Clin Oncol. 14:1995.
16. Scholl S. M., Fourquet A., Asselain B. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results if a randomised trial: S6. Eur J Cancer. 30A:1994;645-652.
17. Semiglazov V. F., Topuzov E. E., Bavli J. L. Primary (neoadjuvant) chemotherapy and radiotherapy compared with radiotherapy alone in stage IIb-IIIa breast cancer. Ann Oncol. 5:1994;591-595.
18. Williams M. R., Gilson D., Marsh L. The early results from a randomised study of radiotherapy versus Nolvadex (tamoxifen) as initial treatment for stage III breast cancer. Eur J Surg Oncol. 14:1988;235-240.
19. Bonadonna G., Veronesi U., Brambilla C. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst. 82:1990;1539-1545.
20. Eisen T., Smith I. E., Johnston S. Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer. J Clin Oncol. 16:1998;1350-1357.
21. Feldman L. D., Hortobagyi G. N., Buzdar A. U., Ames F. C., Blumenschein G. R. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res. 46:1986;2578-2581.
22. Smith I. E., Walsh G., Jones A. High complete remission rates with primary neoadjuvant chemotherapy for large early breast cancer. J Clin Oncol. 13:1995;424-429.
23. Bonadonna G., Valagussa P., Brambilla C. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol. 16:1998;93-100.
24. Brain E., Garrino C., Misset J-L. Long term prognostic and predictive factors in 107 stage II-III breast cancer patients treated with anthracycline based neoadjuvant chemotherapy. Br J Cancer. 75:1997;1360-1367.
25. Honkoop A. H., van Diest P. J., de Jong J. S. Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer. 77:1998;621-626.
26. Kuerer H. M., Newman L. A., Smith T. L. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 17:1999;460-469.
27. Pierga J. Y., Mouret E., Asselain B. Prognostic value of node involvement after preoperative chemotherapy in 507 patients with operable breast cancer. Proc Am Soc Clin Oncol. 17:1998.
28. Schwartzberg L. S., Birch R., Weaver C. H., Campos L., Buckner C. D. High pathological complete response rate to sequential doxorubicin and paclitaxel primary chemotherapy for locally advanced breast cancer (LABC). Proc Am Soc Clin Oncol. 17:1998.
29. Ellis P., Smith I., Ashley S. Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer. J Clin Oncol. 16:1998;107-114.
30. Jacquillat C., Weil M., Baillet F. Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer. 66:1990;119-129.
31. Scholl S. M., Pierga J. Y., Asselain B. Breast tumour response to primary chemotherapy predicts lovcal and distant control as well as survival. Eur J Cancer. 31A:1995;1969-1975.
32. Colleoni M., Nole F., Minchella I. A. Pre-operative chemotherapy and radiotherapy in breast cancer. Eur J Cancer. 34:1998;641-645.
33. Abraham D. C., Jones R. C., Jones S. E. Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging. Cancer. 72:1996;91-100.
34. Therasse P., Mauriac L., Welnicka M. Neo-adjuvant dose intensive chemotherapy in locally advanced breast cancer (LABC): an EORTC-NCIC-SAKK randomized phase III study comparing FEC (5FU, epirubicin, cyclophosphamide) vs high dose intensity EC + G-CSF (filgrastim). Proc Am Soc Clin Oncol. 17:1998.
35. Ayash L. J., Elias P., Ibrahim J. High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma. J Clin Oncol. 16:1998;1000-1007.
36. Diéras V., Fumoleau P., Romieu G. A randomized parallel study of doxorubicin/taxol (AT) and doxorubicin/cyclophosphamide (AC) as neoadjuvant treatment of breast cancer. Breast Cancer Res Treat. 50:1998.
37. Frassoldati A., Banzi M. C., Romagnoli R., Silingardi V. Primary chemotherapy with adriamycin and paclitaxel in breast cancer. Proc Am Soc Clin Oncol. 17:1998.
38. Cameron D. A., Anderson E. D. C., Levack P. Primary systemic therapy for operable breast cancer - 10-year survival data after chemotherapy and hormone therapy. Br J Cancer. 76:1997;1099-1105.
39. Gazet J. C., Coombes R. C., Ford H. T. Assessment of the effect of pretreatment with neoadjuvant therapy on primary breast cancer. Br J Cancer. 73:1996;758-762.
40. Mauriac L., Durand M., Bonichon F., Floquet A. First line tamoxifene for invasive hormonal sensitive non metastatic breast carcinomas in young postmenopausal patients. Eur J Cancer. 32A:1996.
41. Buzdar A., Hortobagyi G. Update on endocrine therapy for breast cancer. Clin Cancer Res. 4:1998;527-534.
42. Soubeyran I., Quénel N., Coindre J. M. pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients. Br J Cancer. 74:1996;1120-1125.
43. Chevillard S., Pouillart P., Beldjord C. Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer. 77:1996;292-300.
44. MacGrogan G., Mauriac L., Durand M. Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GSTπ Br J Cancer. 74:1996;1458-1465.
45. Pierga J. Y., Lainé-Bidron C., Beuzeboc P., De Crémoux P., Pouillart P., Magdelénat H. Plasminogen activator inhibitor-1 (PAI-1) is not related to response to neoadjuvant chemotherapy in breast cancer. Br J Cancer. 76:1997;537-540.
46. Remvikos Y., Beuzeboc P., Zadjela A., Voillemot N., Magdelenat H., Pouillart P. Correlation of pretreatment prolferative activity of breast cancer with response to cytotoxic chemotherapy. J Natl Cancer Inst. 81:1989;1383-1387.
47. Collecchi P., Baldini E., Giannessi P. Primary chemotherapy in locally advanced breast cancer (LABC): Effects on tumour proliferative activity, bcl-2 expression and the relationship between tumour regression and biological markers. Eur J Cancer. 34:1998;1701-1704.
48. Rasbridge S. A., Gillett C. E., Seymour A. M. The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma. Br J Cancer. 70:1994;335-341.
49. Chang J., Powles T. J., Allred D. C. Predictive molecular markers for clinical outcome following primary chemotherapy for operable breast cancer. Proc Am Soc Clin Oncol. 17:1998.
50. Kandioler-Eckersberger D., Taucher S., Steiner B. P53 genotype and major response to anthracyclin or paclitaxel based neoadjuvant treatment in breast cancer patients. Proc Am Soc Clin Oncol. 17:1998.
51. Lancet. 352:1998;930-942.
52. Lancet. 351:1998;1451-1467.